DOCSLIB.ORG

Curriculum Vitae

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Curriculum Vitae Curriculum Vitae PERSONAL INFORMATION Martin Bauer WORK EXPERIENCE December 2004-January 2005 Research associate Medical University of Vienna, Department of Clinical Pharmacology (Austria) Phase I and II studies Pharmacokinetics PET/MR Imaging studies Assessing target tissue penetration with Positron Emission Tomography and Microdialysis DDIs July 2017- Present Senior Consultant Medical University of Vienna, Department of Psychiatry and Psychotherapy (Austria) Outpatients clinic, psychiatric intermediate care unit, emergency psychiatry, memory clinic, Phase II-IV studies March 2011- Present Registered Consultant in Clinical Pharmacology Medical University of Vienna/Vienna General Hospital (Austria) Clinacal pharmacology outpatient clinics, DDIs, pharmacokinetics, microdialysis, PET/MR imaging of ABC transporters, Phase I-II studies March 2014- Present Registered Consultant in Psychiatry Medical University of Vienna/Vienna General Hospital (Austria) General psychiatry, Schizophrenia, affective disorders, dementia, child and adolescent psychiatry March 2015- Present Ethics committee member Medical University of Vienna/Vienna General Hospital (Austria) Reviewing projects, discussion July 2016- Present Associate Professor of Clinical Pharmacology Medical University of Vienna/Vienna General Hospital (Austria) Teaching, provide training, Senior Principal Investigator Clinical Research Phase I-II studies, DDIs, pharmacokinetics, bioequivalence, microdialysis, PET/MR imaging of ABC transporters EDUCATION AND TRAINING January 2005-March 2014 Clinical training (Psychiatry, Clinical Pharmacology) Medical University of Vienna/Vienna General Hospital (Austria) August 2006-August 2006 EudraVigilance User Training Certificate EMEA (United Kingdom) Pharmacovigilance January 2015-October 2015 Research Fellow University of Manchester (United Kingdom) Neuroinflammation and Neurooncology. Preclinical and clinical imaging. ADDITIONAL INFORMATION Expertise Clinical Pharmacology, Target Tissue Pharmacokinetics, Pharmacokinetics, 12/02/2021 European Medicines Agency Page 1/6 Psychiatry, Schizophrenia, Depression, Drug Development, Phase I, Phase II, Blood-Brain Barrier, Drug Transporters, Positron Emission Tomography, Microdosing. Train patient rappresentatives Publications Peer-Reviewed Original Articles 2005-2020 Cumulative impact factor: 277 (125 as first, senior or corresponding author) (* corresponding author, # contributed equally, IF= impact factor) 1.A Weidenauer#, M Bauer#, U Sauerzopf, L Bartova, N Lukas, S Pfaff, C Philippe, N Berroterán-Infante, V Pichler, B Meyer, U Rabl, P Sezen, P Cumming, T Stimpfl, H Sitte, R Lanzenberger, N Mossaheb, A Zimprich, P Rusjan, G Dorffner, M Mitterhauser, M Hacker, L Pezawas, S Kasper, W Wadsak, N Praschak-Rieder, M Willeit. On the relationship of first-episode psychosis to the am-phetamine-sensitized state: A dopamine D2/3 receptor agonist radioligand study. Translational Psychiatry (2020) 10:2 https://doi.org/10.1038/s41398-019-0681-5 IF 2017 5.182 2.N Hommer, M Kallab, S Szegedi, S Puchner, K Stjepanek, M Bauer, R Werkmeister, L Schmetterer, M Abensperg-Traun, G Garhofer, D Schmidl. The effect of orally administered dronabinol on optic nerve head blood flow in healthy subjects- a randomized clinical trial. Clin Pharmacol Ther (2020) 108(1):155-161. doi: 10.1002/cpt.1797 IF 2017 6.544 3.I Hernández Lozano, M Bauer, B Wulkersdorfer, A Traxl, C Philippe, M Weber, S Häusler, B Stieger, U Jäger, S Mairinger, T Wanek, M Hacker, M Zeitlinger, O Langer. Measurement of hepatic ABCB1 and ABCG2 transport activity with [11C]tariquidar and PET in humans and mice. Mol Pharmaceut (2019) [accepted on 02.12.2019] IF 2017 4.556 4.B Wulkersdorfer, M Bauer, R Karch, H Stefanits, C Philippe, M Weber, T Czech, M-C Menet, X Declèves, JA Hainfellner, M Preusser, M Hacker, M Zeitlinger, M Müller, O Langer. Assessment of brain delivery of a model ABCB1/ABCG2 substrate in patients with non-contrast enhancing brain tumors with positron emission tomography. EJNMMI Research (2019) [accepted on 01.12.2019] IF 2017 2.630 5.V Zoufal, S Mairinger, M Brackhan, M Krohn, T Filip, M Sauberer, J Stanek, T Wanek, N Tournier, M Bauer, J Pahnke, O Langer. Imaging P-glycoprotein Induction at the Blood-Brain Barrier of a Beta-Amyloidosis Mouse Model with 11C-Metoclopramide PET. J Nucl Med (2019) [accepted on 18.10.2019] IF 2017 7.439 6.LKS Sundar, O Muzik, L Rischka, A Hahn, R Lanzenberger, M Hienert, E-M Klebermass, M Bauer, I Rausch, E Pataraia, T Traub-Weidinger and T Beyer. The promise of fully-integrated PET/MR imaging: Non-invasive clinical quantification of cerebral glucose metabolism. J Nucl Med (2019) [accepted on 15.07.2019] IF 2017 7.439 7.V Touzeau, M Skoll, P Tajpara, P Kienzl, A Wesinger, S Saluzzo, M Bauer, MC Aichelburg, C Bangert, W Bauer, G Stingl, A Rieger, K Grabmeier-Pfistershammer, C Schuster. Preva-lence of skin-specific autoantibodies in HIV-infected patients and uninfected controls. Acta Dermato-Venereologica (2019) 99(11):978-983. doi: 10.2340/00015555-3251 IF 2017 3.000 8.I Hernández Lozano, R Karch, M Bauer, M Blaickner, A Matsuda, B Wulkersdorfer, M Ha-cker, M Zeitlinger, O Langer. Towards improved pharmacokinetic models for the analysis of transporter-mediated hepatic disposition of drug molecules with positron emission tomogra-phy. AAPS Journal (2019) 21(4):61. doi: 10.1208/s12248-019-0323-0 IF 2017 3.804 9.M Bauer, N Tournier, O Langer. Imaging P-glycoprotein function at the blood-brain barrier as a determinant of the variability in response to CNS drugs. Clin Pharmacol Ther (2019) 105(5):1061-1064. doi: 10.1002/cpt.1402. IF 2017 6.544 10.A Traxl, S Mairinger, T Filip, M Sauberer, J Stanek, S Poschner, W Jäger, V Zoufal, G Novarino, N Tournier, M Bauer, T Wanek, O Langer. Inhibition of ABCB1 and ABCG2 at the mouse blood-brain barrier with marketed drugs to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib. Mol Pharmaceut (2019) 16 (3),12821293 doi: 12/02/2021 European Medicines Agency Page 2/6 10.1021/acs.molpharmaceut.8b01217 IF 2017 4.556 11.N Tournier#, M Bauer#*, V Pichler, L Nics, E-M Klebermass, K Bamminger, S Poschner, P Matzneller, M Weber, F Caillé, S Auvity, S Marie, W Jäger, W Wadsak, Marcus Hacker, M Zeitlinger, O Langer. Impact of P-Glycoprotein Function on the Brain Kinetics of the Weak Sub-strate 11C-Metoclopramide Assessed with PET Imaging in Humans. J Nucl Med (2019) 60(7):985-991. doi: 10.2967/jnumed.118.219972 IF 2017 7.439 12.M Bauer, R Karch, B Wulkersdorfer, C Philippe, L Nics, E-M Klebermass, M Weber, S Poschner, H Haslacher, W Jäger, N Tournier, W Wadsak, M Hacker, M Zeitlinger, O Langer. A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Blood-Brain Barrier. J Nucl Med. (2019) 60:486-491. doi: 10.2967/jnumed.118.216432 IF 2017 7.439 13.M Bauer, A Traxl, A Matsuda, R Karch, C Philippe, L Nics, EM Klebermass, B Wulkersdorfer, M Weber, S Poschner, N Tournier, W Jäger, W Wadsak, M Hacker, T Wanek, M Zeitlinger, O Langer. Effect of rifampicin on the distribution of [11C]erlotinib to the liver, a translational PET study in humans and in mice. Mol Pharm (2018) 1;15(10):4589-4598. doi: 10.1021/acs.molpharmaceut.8b00588. IF 2017 4.556 14.D Amor, S Goutal, S Marie, F Caillé, M Bauer, O Langer, S Auvity, N Tournier. Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib as-sessed with PET imaging in rats. EJNMMI Research (2018) 16;8(1):81 IF 2017 2.630 15.S Auvity, F Caillé, S Marie, C Wimberley, M Bauer, O Langer, I Buvat, S Goutal, N Tournier. P-glycoprotein (ABCB1) inhibits the influx and increases the efflux of 11C-metoclopramide across the blood-brain barrier: a PET study on non-human primates. J Nucl Med (2018). 59(10):1609-1615. doi: 10.2967/jnumed.118.210104. IF 2017 7.439 16.C Schuster, FJ Mayer, C Wohlfahrt, R Marculescu, M Skoll, R Strassl, N Pavo, T Popow-Kraupp, M Hülsmann, M Bauer, MC Aichelburg, A Rieger, G Goliasch. Acute HIV infection results in sub-clinical inflammatory cardiomyopathy. J Infect Dis (2018) 2;218(3):466-470 doi: 10.1093/infdis/jiy183 IF 2017 5.186 17.P Matzneller, M Kussmann, S Eberl, A Maier-Salamon, W Jäger, M Bauer, O Langer, M Zeitlinger, W Poeppl. Pharmacokinetics of the P-gp inhibitor tariquidar in rats after intravenous, oral and intraperitoneal administration. Eur J Drug Metab Pharmacokinet (2018) 43(5):599-606 doi: 10.1007/s13318-018-0474-x. IF 2017 1.362 18.A Chaney, M Bauer#, D Bochicchio#, A Semigova, M Kassiou, KE Davies, SR Williams, H Boutin Longitudinal investigation of neuroinflammation and metabolite profiles in the APPswe×PS1e9 transgenic mouse model of Alzheimers disease. J Neurochem (2018) 144(3):318-335. doi: 10.1111/jnc.14251 IF 2017 4.609 19.M Bauer, A Matsuda, B Wulkersdorfer, C Philippe, A Traxl, C Özvegy-Laczka, J Stanek, L Nics, EM Klebermass, S Poschner, W Jäger, I Patik, E Bakos, G Szakács, W Wadsak, M Hacker, M Zeitlinger, O Langer. Influence of OATPs on hepatic disposition of erlotinib measured with positron emission tomography. Clin Pharmacol Ther (2018) 104(1):139-147. doi: 10.1002/cpt.888 IF 2017 6.544 20.ML Lassen, O Mutzik, T Beyer, M Hacker, CN Ladefoged, J Cal Gonzalez, W Wadsak, I Rausch, M Zeitlinger, O Langer, M Bauer*. Reproducibility of Quantitative Brain Imaging Using a PET-only and a Combined PET/MR System. Front Neurosci (2017) 11:396 doi: 10.3389/fnins.2017.00396. eCollection 2017. IF 2017 3.877 21.M Bauer, B Wulkersdorfer, R Karch, C Philippe, W Jäger, W Wadsak, M Hacker, M Zeitlin-ger, O Langer. Effect of P-glycoprotein inhibition at the blood-brain barrier on brain distribution of (R)-[11C]verapamil in elderly versus young subjects. Br J Clin Pharmacol. (2017) 83(9):1991-9 doi: 10.1111/bcp.13301 IF 2017 3.838 22.A Matsuda, R Karch, M Bauer, A Traxl, M Zeitlinger, O Langer.
Load more

Recommended publications
  • Transition from Acute to Chronic Postsurgical Pain: Risk Factors and Protective Factors
    Review For reprint orders, please contact [email protected] Transition from acute to chronic postsurgical pain: risk factors and protective factors Expert Rev. Neurother. 9(5), 723–744 (2009) Joel Katz† and Most patients who undergo surgery recover uneventfully and resume their normal daily Ze’ev Seltzer activities within weeks. Nevertheless, chronic postsurgical pain develops in an alarming †Author for correspondence proportion of patients. The prevailing approach of focusing on established chronic pain Department of Psychology, implicitly assumes that information generated during the acute injury phase is not important BSB 232, York University, to the subsequent development of chronic pain. However, a rarely appreciated fact is that 4700 Keele Street, Toronto, every chronic pain was once acute. Here, we argue that a focus on the transition from acute ON M3J 1P3, Canada to chronic pain may reveal important cues that will help us to predict who will go on to develop Tel.: +1 416 736 2100 chronic pain and who will not. Unlike other injuries, surgery presents a unique set of ext. 40557 circumstances in which the precise timing of the physical insult and ensuing pain are known Fax: +1 416 736 5814 in advance. This provides an opportunity, before surgery, to identify the risk factors and [email protected] protective factors that predict the course of recovery. In this paper, the epidemiology of chronic postsurgical pain is reviewed. The surgical, psychosocial, socio–environmental and patient- related factors that appear to confer a greater risk of developing chronic postsurgical pain are described. The genetics of chronic postsurgical pain are discussed with emphasis on known polymorphisms in human genes associated with chronic pain, genetic studies of rodent models of pain involving surgical approaches, the importance of developing accurate human chronic postsurgical pain phenotypes and the expected gains for chronic postsurgical pain medicine For personal use only.
    [Show full text]
  • ( 12 ) United States Patent
    US010512655B1 (12 ) United States Patent ( 10 ) Patent No.: US 10,512,655 B1 Brooks (45 ) Date of Patent : Dec. 24 , 2019 ( 54 ) METHODS AND COMPOSITIONS FOR THE Ghosh et al. , “ Methods of Enhancement of Transdermal Drug TOPICAL TREATMENT OF PERIPHERAL Delivery : Part IIB , Chemical Permeation Enhancers ” , Pharmaceu NEUROPATHY tical Technology, 17 ( 5 ) , 68-76 , May 1993 . Swinyard et al ., " Pharmaceutical Necessities ” , Remington's Phar ( 71) Applicant: Jeffrey S. Brooks, Inc., St. Louis , MO maceutical Sciences , 1985, 17th Edition , Chapter 68 , pp . 1278 1320 . (US ) Head , K. , “ Peripheral Neuropathy : Pathogenic Mechanisms and (72 ) Inventor: Jeffrey S. Brooks, St. Louis , MO (US ) Alternative Therapies ” , Alternative Medicine Review , 2006 , 11 ( 4 ) : 294-329 . ( 73 ) Assignee: Jeffrey S. Brooks, Inc., St. Louis , MO Balakumar , P. et al. , “ The multifaceted therapeutic potential of (US ) benfotiamine ” , Pharmacological Research , 2010 , 61 : 482-488 . Fraser , D.A. et al. , “ The effects of long - term oral benfotiamine ( * ) Notice : Subject to any disclaimer , the term of this supplementation on peripheral nerve function and inflammatory patent is extended or adjusted under 35 markers in patients with type 1 diabetes : a 24 -month , double- blind , randomized , placebo -controlled trial ” , Diabetes Care , 2012 , 35 ( 5 ) : 1095 U.S.C. 154 ( b ) by 296 days . 1097 . Fonseca et al. , “ Metanx in Type 2 Diabetes with Peripheral Neuropathy: ( 21) Appl. No .: 14 /202,161 A Randomized Trial” , A Med J , 2013 , 126 ( 2 ) : 141-149 . Filed : Bighley et al ., “ Salt Forms of Drugs and Absorption, ” in Encyclo ( 22 ) Mar. 10 , 2014 pedia of Pharmaceutical Technology , J. Swarbrick and J.C. Boylan , Eds. (Marcel Dekker , New York , 1996 ) , vol.
    [Show full text]
  • Drug Delivery System for Use in the Treatment Or Diagnosis of Neurological Disorders
    (19) TZZ __T (11) EP 2 774 991 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 10.09.2014 Bulletin 2014/37 C12N 15/86 (2006.01) A61K 48/00 (2006.01) (21) Application number: 13001491.3 (22) Date of filing: 22.03.2013 (84) Designated Contracting States: • Manninga, Heiko AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 37073 Göttingen (DE) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO •Götzke,Armin PL PT RO RS SE SI SK SM TR 97070 Würzburg (DE) Designated Extension States: • Glassmann, Alexander BA ME 50999 Köln (DE) (30) Priority: 06.03.2013 PCT/EP2013/000656 (74) Representative: von Renesse, Dorothea et al König-Szynka-Tilmann-von Renesse (71) Applicant: Life Science Inkubator Betriebs GmbH Patentanwälte Partnerschaft mbB & Co. KG Postfach 11 09 46 53175 Bonn (DE) 40509 Düsseldorf (DE) (72) Inventors: • Demina, Victoria 53175 Bonn (DE) (54) Drug delivery system for use in the treatment or diagnosis of neurological disorders (57) The invention relates to VLP derived from poly- ment or diagnosis of a neurological disease, in particular oma virus loaded with a drug (cargo) as a drug delivery multiple sclerosis, Parkinsons’s disease or Alzheimer’s system for transporting said drug into the CNS for treat- disease. EP 2 774 991 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 774 991 A1 Description FIELD OF THE INVENTION 5 [0001] The invention relates to the use of virus like particles (VLP) of the type of human polyoma virus for use as drug delivery system for the treatment or diagnosis of neurological disorders.
    [Show full text]
  • Orally Active Compound Library (96-Well)
    • Bioactive Molecules • Building Blocks • Intermediates www.ChemScene.com Orally Active Compound Library (96-well) Product Details: Catalog Number: CS-L061 Formulation: A collection of 2244 orally active compounds supplied as pre-dissolved Solutions or Solid Container: 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode Storage: -80°C Shipping: Blue ice Packaging: Inert gas Plate layout: CS-L061-1 1 2 3 4 5 6 7 8 9 10 11 12 a Empty Vonoprazan Mivebresib AZD0156 BAY-876 Tomivosertib PQR620 NPS-2143 R547 PAP-1 Delpazolid Empty Varenicline b Empty Varenicline (Hydrochlorid Varenicline A-205804 CI-1044 KW-8232 GSK583 Quiflapon MRK-016 Diroximel Empty e) (Tartrate) fumarate SHP099 c Empty A 922500 SHP099 (hydrochlorid Nevanimibe Pactimibe Pactimibe GNF-6231 MLi-2 KDM5-IN-1 PACMA 31 Empty e) hydrochloride (sulfate) Rilmenidine d Empty Cadazolid Treprostinil GSK3179106 Esaxerenone (hemifumarat Rilmenidine Fisogatinib BP-1-102 Avadomide Aprepitant Empty e) (phosphate) Cl-amidine AZD5153 (6- e Empty Maropitant Abscisic acid (hydrochlorid BGG463 WNK463 Ticagrelor Axitinib Hydroxy-2- CGS 15943 Pipamperone Empty e) naphthoic Setogepram Teglarinad f Empty Y-27632 GSK2193874 Lanabecestat CXD101 Ritlecitinib YL0919 PCC0208009 (sodium salt) (chloride) Futibatinib Empty TAK-659 g Empty NCB-0846 GS-444217 (hydrochlorid Navitoclax ABX464 Zibotentan Simurosertib (R)- CEP-40783 MK-8617 Empty e) Simurosertib Choline JNJ- h Empty CCT251236 (bitartrate) Sarcosine Brensocatib AS-605240 PF-06840003
    [Show full text]
  • Mitigating the Inhibition of Human Bile Salt Export Pump by Drugs
    DMD Fast Forward. Published on September 7, 2012 as DOI: 10.1124/dmd.112.047068 DMD FastThis Forward. article has not Published been copyedited on andSeptember formatted. The 7, final 2012 version as doi:10.1124/dmd.112.047068may differ from this version. DMD #47968 Mitigating the inhibition of human Bile Salt Export Pump by drugs: opportunities provided by physicochemical property modulation, in-silico modeling and structural modification Daniel J. Warner, Hongming Chen, Louis-David Cantin, J. Gerry Kenna, Simone Stahl, Clare L. Walker, Tobias Noeske. Department of Medicinal Chemistry, AstraZeneca R&D Montreal, Montreal, Quebec, H4S Downloaded from 1Z9, Canada (DJW, LDC) Computational Sciences, Discovery Sciences, AstraZeneca R&D Mölndal, Pepparedsleden dmd.aspetjournals.org 1, Mölndal 43183, Sweden (HC) Molecular Toxicology, Global Safety Assessment, AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK (JGK, SS, CLW) Global Safety Assessment, AstraZeneca R&D Mölndal, Pepparedsleden 1, Mölndal 43183, at ASPET Journals on October 10, 2021 Sweden (TN) 1 Copyright 2012 by the American Society for Pharmacology and Experimental Therapeutics. DMD Fast Forward. Published on September 7, 2012 as DOI: 10.1124/dmd.112.047068 This article has not been copyedited and formatted. The final version may differ from this version. DMD #47968 Inhibition of the human Bile Salt Export Pump by drugs. Corresponding author: Tobias Noeske Global Safety Assessment AstraZeneca R&D Mölndal S-431 83 Mölndal, Sweden Phone: +46-31-7064002 Mobile: +46-727-158344
    [Show full text]
  • Effects of Ralfinamide in Models of Nerve Injury and Chemotherapy-Induced Neuropathic Pain
    European Journal of Pharmacology 823 (2018) 27–34 Contents lists available at ScienceDirect European Journal of Pharmacology journal homepage: www.elsevier.com/locate/ejphar Full length article Effects of ralfinamide in models of nerve injury and chemotherapy-induced T neuropathic pain ⁎ ⁎ Xiaonan Liang, Gang Yu , Ruibin Su State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Key Laboratory of Neuropsychopharmacology, Beijing Institute of Pharmacology and Toxicology, 27 Taiping Road, Beijing 100850, China ARTICLE INFO ABSTRACT Keywords: Neuropathic pain is among the most common and difficult-to-treat types of chronic pain and is associated with Neuropathic pain sodium channel malfunction. The sodium channel blocker ralfinamide has exhibited potent analgesic effects in Sodium channel blocker several preclinical pain models and in patients with mixed neuropathic pain syndromes (Phase II trials), but it fi Ral namide failed to ameliorate neuropathic low back pain in Phase III trials. It is unclear whether ralfinamide is effective Analgesic against neuropathic pain induced by specified etiologies. In the present study, the antinociceptive effects of ralfinamide in neuropathic pain models induced by spared nerve injury and chemotherapy were compared in a gabapentin-controlled manner. The effects of ralfinamide on physiological pain were evaluated in mechanical withdrawal, hot plate, and acetic acid writhing tests. We also investigated the effects of ralfinamide on cardi- ovascular function and locomotor activity. Oral ralfinamide dose-dependently alleviated spared nerve injury- induced allodynia in rats and mice. Ralfinamide increased mechanical withdrawal thresholds in oxaliplatin- induced and paclitaxel-induced neuropathic pain. Ralfinamide did not affect physiological pain, locomotion, or cardiovascular function. Together, ralfinamide attenuated mechanical allodynia in all the neuropathic pain models tested, with subtle differences in efficacy.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,076,515 B2 Barbanti Et Al
    USO08076515B2 (12) United States Patent (10) Patent No.: US 8,076,515 B2 Barbanti et al. (45) Date of Patent: Dec. 13, 2011 (54) PROCESS FOR THE PRODUCTION OF 2007/0093495 A1 4/2007 Ruggero et al. 2007/0203182 A1 8, 2007 Besana et al. 2-4-(3- AND 2-FLUOROBENZYLOXY) 2007/0276046 A1 11/2007 Salvati et al. BENZYLAMINO PROPANAMIDES 2008, 0096965 A1 4/2008 Barbanti et al. 2008/O132567 A1 6/2008 Barbanti et al. (75) Inventors: Elena Barbanti, Cologno Monzese (IT): 2010, OO16437 A1 1/2010 Salvati et al. Carla Caccia, Cardano Al Campo (IT): 2010/0324141 A1 12/2010 Barbanti et al. Patricia Salvati, Arese (IT): Francesco 2011/0014304 A1 1/2011 IZZO et al. Velardi, Cameri (IT): Tiziano Ruffili, FOREIGN PATENT DOCUMENTS Vigliano Biellese (IT): Luigi Bogogna, EP 04.00495 A1 12, 1990 Vaprio D'Agogna (IT) EP 1655O29 A 5, 2006 WO WO 2004/066987 A2 8, 2004 (73) Assignee: Newron Pharmaceuticals S.p.A., WO WO 2005/040138 A1 5, 2005 Bresso (IT) WO WO 2005,102300 A1 11/2005 WO WO 2006/027052 A2 3, 2006 (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 OTHER PUBLICATIONS U.S.C. 154(b) by 551 days. Stummann et al., 2005. “The anti-nociceptive agent ralfinamide inhibits tetrodotoxin-resistant and tetrodotoxin-sensitive Na+ cur (21) Appl. No.: 12/338,825 rents in dorsal root ganglion neurons.” European Journal of Phar macology, 510: 197-208. (22) Filed: Dec. 18, 2008 Cattabeni, 2004, “Ralfinamide.” Idrugs, Current Drugs Ltd., pp.
    [Show full text]
  • Sodium Channel Na Channels; Na+ Channels
    Sodium Channel Na channels; Na+ channels Sodium channels are integral membrane proteins that form ion channels, conducting sodium ions (Na+) through a cell's plasma membrane. They are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). In excitable cells such as neurons, myocytes, and certain types of glia, sodium channels are responsible for the rising phase of action potentials. Voltage-gated Na+ channels can exist in any of three distinct states: deactivated (closed), activated (open), or inactivated (closed). Ligand-gated sodium channels are activated by binding of a ligand instead of a change in membrane potential. www.MedChemExpress.com 1 Sodium Channel Inhibitors, Agonists, Antagonists, Activators & Modulators (+)-Kavain (-)-Sparteine sulfate pentahydrate Cat. No.: HY-B1671 ((-)-Lupinidine sulfate pentahydrate) Cat. No.: HY-B1304 (+)-Kavain, a main kavalactone extracted from Piper (-)-Sparteine sulfate pentahydrate ((-)-Lupinidine methysticum, has anticonvulsive properties, sulfate pentahydrate) is a class 1a antiarrhythmic attenuating vascular smooth muscle contraction agent and a sodium channel blocker. It is an through interactions with voltage-dependent Na+ alkaloid, can chelate the bivalents calcium and and Ca2+ channels. magnesium. Purity: 99.98% Purity: ≥98.0% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 5 mg, 10 mg Size: 10 mM × 1 mL, 50 mg (Rac)-AMG8379 20(S)-Ginsenoside Rg3 ((Rac)-AMG8380) Cat. No.: HY-108425B (20(S)-Propanaxadiol; S-ginsenoside Rg3) Cat.
    [Show full text]
  • Preventive Analgesia: Quo Vadimus?
    REVIEW ARTICLE Preventive Analgesia: Quo Vadimus? Joel Katz, PhD,*§¶ Hance Clarke, MSc, MD,§¶ and Ze’ev Seltzer, BMS, DMD§# The classic definition of preemptive analgesia requires 2 groups of patients to receive identical treatment before or after incision or surgery. The only difference between the 2 groups is the timing of administration of the drug relative to incision. The constraint to include a postincision or postsurgical treatment group is methodologically appealing, because in the presence of a positive result, it provides a window of time within which the observed effect occurred, and thus points to possible mechanisms underlying the effect: the classic view assumes that the intraoperative nociceptive barrage contributes to a greater extent to postoperative pain than does the postoperative nociceptive barrage. However, this view is too restrictive and narrow, in part because we know that sensitization is induced by factors other than the peripheral nociceptive barrage associated with incision and subsequent noxious intraoperative events. A broader approach to the prevention of postoperative pain has evolved that aims to minimize the deleterious immediate and long-term effects of noxious perioper- ative afferent input. The focus of preventive analgesia is not on the relative timing of analgesic or anesthetic interventions, but on attenuating the impact of the peripheral nociceptive barrage associated with noxious preoperative, intraoperative, and/or postoperative stimuli. These stimuli induce peripheral and central sensitization, which increase postoperative pain intensity and analgesic requirements. Preventing sensitization will reduce pain and analgesic requirements. Preventive analgesia is demonstrated when postoperative pain and/or analge- sic use are reduced beyond the duration of action of the target drug, which we have defined as 5.5 half-lives of the target drug.
    [Show full text]
  • (DTX) 217 – Selectivity 219 A-278637
    467 Index a – pentylenetetrazol 357 ff. a interaction domain 71 – picrotoxin 357 a1 subunit 69 ff. antiepileptic drugs, receptor sites 9 a2-d subunit 57, 69 ff. antiepileptics 87 a-Dendrotoxin (DTX) 217 anxiety 369 – selectivity 219 – canopy test 369 ff. A-278637 344 ff. apamin 242, 244, 326 f. A- 411873 323 apoptosis 237 acetylcholine receptor deficiency 408 –Fas receptor 237 AChR 410 – mitochondria 237 action potential 44, 55 aryloxindole 321 adipocytes 244 ff. arylpyrrole 323 – brown fat 244 asthma 324 – glucose transporter 244 ATP-sensitive potassium channel KATP 335, – white fat 244 385 afterhyperpolarization 314 atrial effective refractory period (AERP) Agenelopsis aperta 131 291 alkaloid 319, 328 atrial fibrillation 276 ALMOND modul 432 ff. atrial vulnerability 291 Alzheimer’s disease 317 autism 396 ambasilide 278 autoantibodies 238 amiloride-sensitive epithelial sodium autoimmune diseases 247 ff. channel 397 autosomal dominant 4-aminopyridine 222 – juvenile myoclonic epilepsy 412 amiodarone 29, 278 – nocturnal frontal lobe epilepsy 410 amitriptyline, NaV blocking activity 186 auxiliary subunit in amlodipine 89 ff. –Kvb 11 amygdala-kindling model 357 ff., 361 – KChIp1-4 11 anandamide 91 – minK 11 ancillary calcium channel subunits 69 ff., auxiliary subunits 77 –Cava210 Andersen-Tawil syndrome 383 –Cavb 10 anesthetics 87 –Cavd 10 anosmia 251 –Cavg 10 antiarrhythmic drugs 9, 278 –Navb19 anticonvulsant –ofK+ channels 198 – amygdala-kindling 357 ff. AVE0118 287, 289 –6Hz model 361 azaindole 323 – maximal electroshock 357 ff. azimilide 278 Voltage-Gated Ion Channels as Drug Targets. Edited by D. Triggle Copyright c 2006 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim ISBN 3-527-31258-7 468 Index b – dialkyl-dipeptidylamines 132 b cell rest 341 – dihydropyridines 139 ff.
    [Show full text]
  • | Hao Watum Ut Til a T Man at Malat
    |HAO WATUM UT US010087143B2TIL A T MAN AT MALAT (12 ) United States Patent (10 ) Patent No. : US 10 , 087 , 143 B2 Hadida - Ruah et al. (45 ) Date of Patent: * Oct. 2 , 2018 ( 54 ) PYRIDONE AMIDES AS MODULATORS OF 8 , 779 , 197 B2 7 / 2014 Chen 8 , 841, 483 B2 9 /2014 Joshi SODIUM CHANNELS 8 , 865, 771 B2 10 / 2014 Chen 9 ,051 , 270 B2 * 6 /2015 Hadida - Ruah .. .. C07D 213 / 75 ( 71 ) Applicant: VERTEX PHARMACEUTICALS 9 , 108 ,903 B28 /2015 Hadida - Ruah INCORPORATED , Boston , MA (US ) 9 , 139 ,529 B2 9 /2015 Hadida - Ruah 9 , 163 ,042 B2 10 /2015 Anderson (72 ) Inventors : Sara Sabina Hadida - Ruah , La Jolla , 9 , 393 ,235 B2 * 7 / 2016 Hadida -Ruah .. .. .. CO7D 213 / 75 CA (US ) ; Corey Anderson , San Diego , 9 ,421 , 196 B2 8 /2016 Hadida - Ruah CA (US ) ; Vijayalaksmi Arumugam , 9 , 464 , 102 B2 10 / 2016 Anderson San Marco , CA (US ) ; Iuliana Luci (Continued ) Asgian , San Diego , CA ( US ) ; Brian Richard Bear , Carlsbad , CA (US ) ; FOREIGN PATENT DOCUMENTS Andreas P . Termin , Encinitas, CA CN 101883758 11 / 2010 (US ) ; James Philip Johnson , San CN 102264722 11/ 2011 Diego , CA (US ) (Continued ) (73 ) Assignee : VERTEX PHARMACEUTICALS INCORPORATED , Boston , MA (US ) OTHER PUBLICATIONS ( * ) Notice: Subject to any disclaimer, the term of this Akopian , A . N ., L . Sivilotti, and J. N . Wood , “ A tetrodotoxin patent is extended or adjusted under 35 resistant voltage - gated sodium channel expressed by sensory neu U . S . C . 154 (b ) by 0 days . rons .” Nature , 1996 . 379 ( 6562 ) : p . 257 -62 ). This patent is subject to a terminal dis ( Continued ) claimer .
    [Show full text]
  • Product List
    PRODUCT LIST Active Pharma Ingredients API Acid Reflux Disorders Product Pharmacopoeia CAS No. Technical Document A Acotiamide Hydrochloride - 773092-05-0 - Almagate EP 66827-12-1 - Aluminum Hydroxide BP, USP 21645-51-2 - C Cimetidine - 51481-61-9 - D Dexlansoprazole - 138530-94-6 - Dexlansoprazole - 313640-86-7 DMF Sesquihydrate Dexrabeprazole Sodium - 171440-18-9 ODMF, Tech Pack E Ecabet Sodium - 86408-72-2 DMF Esomeprazole - 119141-88-7 - Esomeprazole Magneisum - 217087-10-0 - Dihydrate Esomeprazole Magnesium - 161973-10-0 - Esomeprazole Magnesium USP 217087-09-7 CEP, DMF Trihydrate Esomeprazole Potassium IHS 161796-84-5 DMF Esomeprazole Sodium - 161796-78-7 - Esomeprazole Zinc/ 793668-08-3, - - Base/Strontium 119141-88-7 F Famotidine - 76824-35-6 - E Glycopyrrolate - 596-51-0 - H Hydrotelcite BP 12304-65-3 - I Ilaprazole IHS, IP 172152-36-2 DMF Ilaprazole Sodium - 172152-50-0 ODMF, Tech Pack Itopride - 122898-67-3 - Itopride Hydrochloride IHS 122892-31-3 - Patent Disclaimer: Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. 2021-01-11 © ExSyn Corp | All rights reserved. | www.exsyncorp.com 1 API Acid Reflux Disorders Product Pharmacopoeia CAS No. Technical Document L Lafutidine - 118288-08-7 - Lansoprazole - 103577-45-3 - Lansoprazole Sodium - 226904-00-3 - M Magaldrate USP 74978-16-8
    [Show full text]